I do agree cash burn increase by aporox 275k
correct me if I am wrong on calculation on R&D exp.
received $1.6m
product manufacturing cost -$882k
net r&d $718k
add$211k limepay having cash
total ip $934k
cash at end of q $7174k and last q$6517k difference $700k minus $934 ip i.e., r&d so cash burn is -275k.
agreed r&d cost is one of cost but that cost eventually increases revenue and that's what we are seeing from this q the revenue increase to $3.5m which is good result.
any cost in r&d is future revenue thats how the products are developed and delivered for fit to purpose. IMO every IT company they have to churn money in development as constantly changing technology, competitors and clients requirements etc..
so I don't think so cash would be concern going forward.
there are some notes on further cost reduction, product enhancement and revenue generation that will be seen in any new announcements or next 4c
- Forums
- ASX - By Stock
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
SPX
spenda limited
Add to My Watchlist
21.4%
!
0.6¢

I do agree cash burn increase by aporox 275kcorrect me if I am...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.6¢ |
Change
-0.002(21.4%) |
Mkt cap ! $25.38M |
Open | High | Low | Value | Volume |
0.7¢ | 0.7¢ | 0.5¢ | $11.29K | 1.872M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
50 | 26689523 | 0.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.6¢ | 336560 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
50 | 26689523 | 0.005 |
8 | 15700000 | 0.004 |
8 | 25200000 | 0.003 |
3 | 4500001 | 0.002 |
4 | 8990002 | 0.001 |
Price($) | Vol. | No. |
---|---|---|
0.006 | 336560 | 4 |
0.007 | 17197256 | 21 |
0.008 | 5622738 | 28 |
0.009 | 11710538 | 17 |
0.010 | 1346835 | 6 |
Last trade - 15.59pm 26/06/2025 (20 minute delay) ? |
Featured News
SPX (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online